Paxalisib
- Generic Name
- Paxalisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22N8O2
- CAS Number
- 1382979-44-3
- Unique Ingredient Identifier
- P5DKZ70636
- Background
GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).
- Associated Conditions
- -
- Associated Therapies
- -
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial
Kazia Therapeutics presented EVT801 data at the 15th Biennial Ovarian Cancer Research Symposium, showing promising activity in high grade serous ovarian cancer, with 46% of patients having stable disease or partial response.
Immunotherapy Clinical Trial News - Stocks to Watch
Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.
July 2024
July's Molecules of the Month feature Novartis' molecular glue degrader for sickle cell disease, Pfizer's tinlorafenib for melanoma with brain metastasis, AstraZeneca's AZ-PRMT5i-1 for MTAP-deficient cancers, MTX-531 for dual EGFR/PI3K inhibition, and LifeMine Therapeutics' XC219 discovered via top-down approach. Paxalisib shows promising data in glioblastoma, and Takeda's OX2R-selective agonist offers potential in Alzheimer's disease.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath